Biotech firm PPL Therapeutics was back in the headlines earlier this year when it produced genetically-modified five piglets, which it said had the potential to provide organs for human patients. The shares surged on the news, but two months later shares slid after its cloned sheep Dolly developed arthritis. On Monday the group is expected to report full-year losses of £12.8m, against a loss for the previous year of £12m. Analysts want an update on the piglets' progress.